NCT Number: NCT01973478
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
Patients with TRD are potential candidates for neurosurgical interventions to treat depression. However, psychosurgery interventions based upon lesions, showed their limitations related to 1. the large variability in neurosurgical gestures, 2. their side effects, and of course 3. the irreversible damage caused by the surgery.
Thus, deep brain stimulation (DBS) could represent an opportunity for patients suffering from TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging results. The investigators have thus planned a randomized controlled trial versus sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
APHM, Marseille, France
About this study
Because of their recurrent nature, their prevalence and their consequences, major depressive disorders are real public health issues in terms of diagnosis and treatment.
Some forms of depression are chronic and resistant to treatment (TRD), either unipolar (repeated episodes of depression) or bipolar (repeated episodes of depression and manic and/or hypomanic episodes). In these forms suicide risk is important.
Patients with TRD are potential candidates for neurosurgical interventions to treat depression. The benefit of neurosurgical procedures is expected to be important in these patients.
Psychosurgery interventions based upon lesions, however, showed their limitations related to 1/ the large variability in neurosurgical gestures, 2/ their side effects, and of course 3/ the irreversible damage caused by the surgery.
Current brain imaging data yielded fresh information about the pathophysiology of depression and suggested new therapeutic approaches in TRD.
Modulation of sub-caudate specific pathways, which are part of orbitofrontal and anterior cingulate cortico-subcortical loops should allow for a diminution of depressive symptoms.
The modulation of these specific pathways, initially targeted by classical neurosurgery, could benefit from current developments in functional neurosurgery.
Deep brain stimulation (DBS) may represent an opportunity for patients suffering from TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging results. The investigators have thus planned a randomized controlled trial versus sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age between 18 and 70 years
- DSM-IV (DSM = Diagnostic and Statistical Manual) criteria for a recurrent depressive disorder or bipolar disorder
- Duration of the episode > 2 years
- Severity of the episode attested by :
- A HDRS score > 21
- A CGI score ≥ 4
- A GAF < 50
- Persistence of severity criteria during the screening
- Following characteristics resistance in case of recurrent depressive disorder :
- Stage V of the classification of Thase and Rush
- Unsuccessful treatment by the association of two antidepressants (or intolerance/contra-indications)
- Unsuccessful treatment by the association for at least 6 weeks of one of the following treatments : lithium , thyroid hormone , buspirone , pindolol with an antidepressant (or intolerance/contra-indications)
- Unsuccessful treatment by the combination of a second-generation antipsychotic (olanzapine, risperidone, amisulpride, aripiprazole, clozapine and quetiapine) to an antidepressant (or intolerance/contra-indications)
- Unsuccessful treatment by a structured psychotherapy
- Following characteristics of resistance in case of bipolar disorder:
- Unsuccessful treatment by lithium (or intolerance/contra-indications)
- Unsuccessful treatment by at least one mood stabilizer anticonvulsant (or intolerance/contra-indications)
- Unsuccessful treatment by at least one second-generation antipsychotic (or intolerance/contra-indications)
- Unsuccessful treatment by the combination of two mood stabilizers with at least an anticonvulsant (or intolerance/contra-indications)
- Unsuccessful treatment by electro-convulsive therapy sessions (or intolerance/contra-indications)
- Unsuccessful treatment by at least one antidepressant , mood stabilizer combination (or intolerance/contra-indications)
- Unsuccessful treatment by a structured psychotherapy
- Understanding the conduct of the study
- Giving a written informed consent
- Benefiting from the french social insurance
Non-Inclusion Criteria:
- Comorbid axis 1 disorder (except dysthymia, generalized anxiety disorder, social phobia, panic disorder)
- Alcohol or other psychoactive substances dependence (except nicotine)
- Suicidal risk during the last month assessed by the MINI (Mini International Neuropsychiatric Interview), the DIGS (Diagnostic Interview for Genetic Studies) and the item 3 of the HDRS
- Suicide attempt in the last 6 months or two suicide attempts in the previous two years
- History of forensic act or furious mania
- Depressive episode with congruent or incongruent psychotic features or history of a depressive episode with psychotic features
- Comorbid cluster A or B personality disorders according to the DSM IV-TR evaluated using the SCID2 (Structured Clinical Interview for DSM-IV)
- Cognitive Impairment (Mattis < 130)
- MRI (Magnetic Resonance Imaging) contraindication to stimulation or contraindications for MRI
- Major somatic disease making it impossible to set up the study treatment
- Pregnant women, or nursing or childbearing potential without effective contraception
- Involuntary commitment
- Guardianship
- Participation in another study
Treatment and study plan
SHAM
DevicePrimary outcomes
-
Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no)
Time frame: Month 7
Response is defined as a 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version)
Secondary outcomes
-
Remission (yes/no)
Time frame: Month 7
Remission is defined as an HDRS-17 score < 7
-
CGI (Clinical global impressions) amelioration (yes/no)
Time frame: Month 7
Score of 1 or 2 (item 2 of the CGI)
-
GAF (Global assessment of functioning)
Time frame: Month 7
Presence of a score ≥ 60
-
HDRS-17 (Hamilton depression rating scale, 17 items version)
Time frame: Month 7
Score
-
MADRS (Montgomery-Asberg Depression Rating Scale)
Time frame: Month 7
Score
-
BDI (Beck Depression Inventory)
Time frame: Month 7
Score
-
CGI (Clinical global impressions)
Time frame: Month 7
Score
-
LARS (Lille Apathy Rating scale)
Time frame: Month 7
Score
-
GAF (Global assessment of functioning)
Time frame: Month 7
Score
-
Neuropsychological assessment
Time frame: Day -7 ; Month 1; Month 7; Month 13; Month 19; Month 24
-
Cerebral metabolism (PET scans)
Time frame: Day -7; Month 7
-
Adverse events
Time frame: Month 24
Adverse events occuring during the study.
Other outcomes
-
HDRS-17 (Hamilton depression rating scale, 17 items version)
Time frame: Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24
Longitudinal evolution of the score
-
MADRS (Montgomery-Asberg Depression Rating Scale)
Time frame: Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24
Longitudinal evolution of the score
-
BDI (Beck Depression Inventory)
Time frame: Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24
Longitudinal evolution of the score
-
CGI (Clinical global impressions)
Time frame: Month -3 ; Month -1; Day-7; Day15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24
Longitudinal evolution of the score
-
LARS (Lille Apathy Rating scale)
Time frame: Day -7; Month 1; Month 7; Month 13; Month 19; Month 24
Longitudinal evolution of the score
-
GAF (Global assessment of functioning)
Time frame: Month -3 ; Month -1; Day -7; Month 1; Month 7; Month 13; Month 19; Month 24
Longitudinal evolution of the score
-
YMRS (Young Mania Rating Scale)
Time frame: Day -7; Month 1; Month 7; Month 13; Month 19; Month 24
Longitudinal evolution of the score
-
MATHYS (Multidimensional Assessment of Thymic States)
Time frame: Day -7; Month 1; Month 7; Month 13; Month 19; Month 24
Longitudinal evolution of the score
-
Response (50 % decrease of the HDRS-17)
Time frame: Month 24
During the whole follow up
-
Remission
Time frame: M24
During the whole follow up Remission is defined as an HDRS-17 score < 7
Sponsors and collaborators
Lead sponsor
Rennes University Hospital
Other
Registry information
Acronym: STHYM
Important dates
- Study start
- 2014
- Primary completion
- 2017
- Study completion
- 2018
- First posted
- Oct 31, 2013
- Registry last updated
- Dec 27, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
NCT01269710
Autism Spectrum Disorder, Autistic Disorder
Chapel Hill, North Carolina, United States
View Trial DetailsThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
NCT05786066
Behavior, Behavioral Symptoms
West Haven, Connecticut, United States
View Trial DetailsUsing mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders
NCT04675593
Behavior, Bipolar Disorder
Cleveland, Ohio, United States
View Trial DetailsImaging mGluR5 and Synaptic Density in Psychiatric Disorders
NCT03898297
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial Details